Meiji Seika Pharma Co., Ltd. engages in the business of manufacture and distribution of pharmaceutical products. It also engages in the animal health business. The company was founded on October 9, 1916 and is headquartered in Tokyo, Japan.

Established in 1992 as an export-oriented unit (EOU), Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing. We today rank among the top 15 pharmaceutical companies in India and enjoy a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products. Their pharmaceutical solutions include active pharmaceutical ingredients (API), finished dosage forms, new drug discovery (NDD), novel drug delivery systems (NDDS) and contract research and manufacturing services (CRAMS). They are globally present across 70+ countries through alliances, joint ventures and partnerships with globally reputed majors.

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Elan Pharma International Ltd., a subsidiary of Perrigo Co. Plc, is a company headquartered in South San Francisco, CA, that develops, manufactures and distributes pharmaceutical products.

SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. Its products include antibiotics, cures for the circulatory and respiratory system, medicines for the digestive system and ophthalmology, and anti-inflammatory. The company was founded on December 29, 1943 and is headquartered in Hwaseong-si, South Korea.

Shandong Yuxin Pharmaceutical Co., Ltd., established on 2010-12-30, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;Drug retail;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Disinfectant production(Free of Hazardous Chemicals);Catering Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Pharmaceutical commissioned production;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Production of labor protection products;Sales of labor protection products;Disinfectant sales(Free of Hazardous Chemicals);Medical Research and Experimental Development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

TAP Pharmaceutical Products was formed in 1977 as a joint venture between the two global pharmaceutical companies, Abbott Laboratories and Takeda Pharmaceutical Co. The company markets Prevacid and Lupron Depot, both leaders in their classes. Joint venture came to an end in March 2008 and Takeda took over the TAP. Lupron Depot is indicated for the palliative treatment of advanced prostate cancer, for management of endometriosis, in combination with iron for the preoperative treatment of anemia caused by uterine fibroids, and for the treatment of children with central precocious puberty.

Zhejiang Huafang Pharmaceutical Co., Ltd formerly Zhejiang Huangyan Sifang Chemical Factory, founded in September 1993, November 2007 changed its name to Zhejiang Fang Pharmaceutical Co., Ltd. Founded in June 2015 Zhejiang Pharmaceutical Co., Ltd., in November 2015 in the three new board officially listed (code 833776). The company is headquartered in Zhejiang Huangyan Economic Development Zone, Jiangkou lightweight Investment Zone, covers an area of ​​46666.9m2, construction area of ​​32009 m2, the total assets of 300 million yuan, 150 million yuan in fixed assets. In 2005, Shandong Weifang Shandong invested 160 million established four subsidiaries. Company employees 450 people, including technical personnel more than 180 people. Company for the state high-tech enterprises, with the provincial high-tech research and development centers, Taizhou academician workstation. Company and Lanzhou University, Shenyang Pharmaceutical University, East China University of Technology, Fudan University, Zhejiang University, Zhejiang University and other institutions of higher learning established long-term cooperative relationship. Companies included in the national technological innovation fund a project, the State Torch Program 3, a national key new products, high-tech products 9 provincial and municipal high-tech products 6, 7 invention patents, continuous eleven was named Huangyan District top 100 enterprises.

Sichuan Kelun Pharmaceutical Co., Ltd. engages in research, development, manufacture, and sale of pharmaceutical products. Its products include large volume injection (infusion), small capacity injection (water injection), sterile powder injection, tablets, capsules, granules, oral solution, and peritoneum. It also provides dialysate and antibiotic intermediates, raw materials, pharmaceutical packaging materials, medical equipment, and other medical products. The company was founded by Ge Xin Liu in 1996 and is headquartered in Chengdu, China.

Shandong Changyi Sifang Pharmaceutical Chemical Co., Ltd., established on 2005-09-14, Business scope includes production and sales:Sodium Hydrosulfide(Limited period subject to license).Production and sales:demethyl ester(EHATA),Acetylaminothiadiazole(EAMTD),Dimercaptothiadiazole(DMTD),Desmethylthiadiazole(MTD),AEactive ester(MAEA),Aztreonam,BTPA(cefcapine side chain acid),Tolnaftate,SMIA(ammonium furan),FR-3990acid,(6R,7R)-7-Phenylacetylamino-2-a-3-hydroxyl-8-Oxo-5-sulfur-1-Azabicyclo[4.2.0]pungent-2-Diphenylmethyl carboxylate(HCA).Import and export of goods and technology.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

These words reflects the company's mission statement since its inception in 1988 and will continue to do so in the coming future. Each and every word in the mission statement has been carefully choosen to reflect our company strategy in order to live up to the expectations and standards envisioned by it. Tough competition by market globalization drives us to deliver high quality products through innovation that encapsulates new ideas and collaboration to encourage creativity. In addition, Farenheit is seeking to expand its lineup by seeking collaboration with partners overseas to develop and distribute licensed new products. Partnership like these allows the construction of distribution networks for the company which can provide us with new opportunities to expand beyond the local market. Together with our local products, Fahrenheit is able to deliver new products and concepts to provide customers with products that meet their needs, keeping in mind the mission statement.

Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL.

Yungjin Pharm. Co., Ltd. engages in the development, production, and distribution of pharmaceuticals. Its products include cephalosporin, antibiotics, drugs for the central nervous system, cardiovascular, endocrine system, urinary system, respiratory, anti-inflammatory and analgesics, anti-histamine, anti-fungal, total nutrition, vitamin and supplement, cosmetics, and tonic drinks. The company was founded on July 16, 19672 and is headquartered in Seoul, South Korea.

Qilu Anti Pharmaceutical Co., Ltd., established on 1995-05-29, The scope of business includes drugs and their pharmaceutical intermediates within the scope of drug production license approval,production of by-products,Sales;General cargo,dedicated transport(refrigeration);Catering Services(The operating permit).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Je Il Pharm Co., Ltd. is a private company headquartered in Daegu, the South Korea, that manufactures and sells pharmaceutical products.

Zhejiang Dongbang Pharmaceutical Co., Ltd., established on 2004-08-09, Business scope includes raw materials(Cefaclor,Cefixime,cefdinir,Faropenem Sodium)manufacture(Operate with a valid license);Organic intermediate,Inorganic salt manufacturing(Free of hazardous chemicals and precursor chemicals);Import and export of technology and goods.

Wockhardt Ltd. is a Global pharmaceutical and biotechnology company headquartered in Mumbai, India. The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. It is a global company with more than half of its revenue coming from Europe. In 2011–2012 its UK and USA sales alone were US$475 million. It has market presence in emerging markets such as Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. The Company has a market capitalisation of over ₹211 billion (US$3.1 billion) and an annual turnover of ₹36 billion (US$520 million). It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company employs over 8,600 people globally. Wockhardt Hospitals is a subsidiary of the Wockhardt Group.

Lunanbeite Pharmaceutical Co., Ltd., established on 2003-12-16, Business scope includes production,Sales:Western medicine,Chemical raw materials and preparations,Psychotropic drugs,Pharmaceutical Intermediates,Health products,food,medical instruments,cosmetic(Limited to production in industrial parks);drug research and development;Domestic Trade;Import and export of goods and technology;Sales of chemical products(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd., established on 2011-04-11, The business scope includes Chinese and Western medicines,Development of pharmaceutical raw materials,to develop;API,Antitumor raw materials,Sterile API,Chemical raw materials for pharmaceutical production,Production of excipients and intermediates,Sales(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. engages in the manufacture, sale, research and development of pharmaceutical products. Its products include anti-infective, antiviral, respiratory system, digestive system, nervous, endocrine, cardiovascular system, antipyretic, analgesics & anti-inflammatory, oncology, anti-allergic APIs & intermediates, lyophilized powder for injection preparation, solid preparation, chemical raw medicine, cephalosporin raw medicine and oral cephalosporin series. The company was founded on December 14, 1995 and is headquartered in Linyi, China.